Ratings Abbott Laboratories Swiss Exchange

Equities

ABT

US0028241000

Market Closed - Swiss Exchange Other stock markets 11:31:05 2024-02-19 am EST			5-day change	1st Jan Change
93 ^CHF	-.--%		-.--%	-.--%

Apr. 29	Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee	MT
Apr. 26	Dexcom's profit beats estimates on strong glucose monitor demand	RE

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.31 times its estimated earnings per share for the ongoing year.
With an enterprise value anticipated at 4.59 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
ABBOTT LABORATORIES	-.--%	187B	-
MEDTRONIC PLC	-1.85%	106B	C
BECTON, DICKINSON AND COMPANY	-4.26%	66.9B	A
DEXCOM, INC.	+1.39%	49.45B	B-
CENCORA, INC.	+16.82%	48B	B-
HOYA CORPORATION	+5.82%	40.84B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+3.49%	26.48B	B
WEST PHARMACEUTICAL SERVICES, INC.	+0.65%	26.25B	A-
TERUMO CORPORATION	+17.42%	24.62B	A-
ZIMMER BIOMET HOLDINGS, INC.	+0.01%	24.52B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes